Related Experiment Video
Updated: May 4, 2026

Scalable 96-well Plate Based iPSC Culture and Production Using a Robotic Liquid Handling System
Published on: May 14, 2015
Induced pluripotent stem cells in regenerative medicine and disease modeling
Graham G Walmsley, Jeong Hyun, Adrian McArdle
1Hagey Laboratory for Pediatric Regenerative Medicine, Stanford University School of Medicine, 257 Campus Drive, Stanford University, Stanford, CA 94305-5148, USA. dwan@stanford.edu.
Abstract:
In 2006, Dr. Yamanaka created the induced pluripotent stem cell (iPSC) by reprogramming adult fibroblasts back to an immature, pluripotent state. Effectively bypassing the ethical constraints of human embryonic stem cells, iPSCs have expanded the horizons of regenerative medicine by offering a means to derive autologous patient-matched cells and tissues for clinical transplantation. However, persisting safety concerns must be addressed prior to their widespread clinical application. In this review, we discuss the history of iPSCs, derivation strategies, and current research involving gene therapy and disease modeling. We review the potential of iPSCs for improving a range of cell-based therapies and obstacles to their clinical implementation.
Related Concept Videos
EPS and iPS Cells in Disease Research
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Somatic...
Induced Pluripotent Stem Cells
iPS Cell Differentiation
Stem Cell Culture

